Literature DB >> 28477732

Focus on growth hormone deficiency and bone in adults.

Nicholas A Tritos1.   

Abstract

Growth hormone (GH) exerts several effects on the skeleton, mediated either directly or indirectly, leading to increased bone formation and resorption rates. Patients with growth hormone deficiency (GHD) of adult onset have decreased bone mineral density (BMD) and increased fracture risk. Some, but not all, studies have found that adults with childhood onset GHD also have lower BMD than healthy controls. Adults with GHD of childhood onset have smaller bone dimensions, leading to possible underestimation of areal BMD (measured by dual energy X-ray absorptiometry), thus potentially confounding the interpretation of densitometric data. Available data suggest that patients with childhood onset GHD are at increased fracture risk. Prospective studies and some clinical trials found that GH replacement for at least 18-24 months leads to increased BMD. Retrospective and prospective data suggest that GH replacement is associated with decreased fracture risk in adults. However, data from randomized clinical trials are lacking.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  bone mineral density; fracture; growth hormone deficiency; growth hormone replacement; hypopituitarism; skeleton

Mesh:

Substances:

Year:  2017        PMID: 28477732     DOI: 10.1016/j.beem.2017.02.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  2 in total

1.  Lower Oxytocin Levels Are Associated with Lower Bone Mineral Density and Less Favorable Hip Geometry in Hypopituitary Men.

Authors:  Anna Aulinas; Francisco J Guarda; Elaine W Yu; Melanie S Haines; Elisa Asanza; Lisseth Silva; Nicholas A Tritos; Joseph Verbalis; Karen K Miller; Elizabeth A Lawson
Journal:  Neuroendocrinology       Date:  2020-02-20       Impact factor: 4.914

2.  Towards preventive pharmacovigilance through medicine misuse identification: an example with recombinant human growth hormone for aesthetic purposes.

Authors:  Alfredo J Rodrigues-Neto; Camila Biazoni-Albaricci; Adalton Ribeiro; Silvana Lima; Albert Figueras
Journal:  Eur J Clin Pharmacol       Date:  2018-07-23       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.